Insulet data shows Omnipod 5's superiority to regular pump therapy
WEBMar 8, 2024 · Results demonstrated significantly lower mean glucose and time above 180 mg/dL in the Omnipod 5 group. That group also spent significantly less time below 70 mg/dL. Mean time decreased from 1.66% to 1.18% with Omnipod 5, compared to an increase from 1.66% to 1.75% in the control group. Time below 54 mg/dL proved non …
Know Labs unveils wearable, non-invasive CGM set to go to FDA
WEBFeb 27, 2024 · A rendering of the KnowU non-invasive glucose monitor. [Image courtesy of Know Labs] Know Labs (NYSE:KNW) today unveiled KnowU, its wearable, non-invasive continuous glucose monitor (CGM) system. Seattle-based Know Labs first announced its initial prototype last June.It says KnowU is the result of an accelerated development …
i2o looks to revive diabetes drug-eluting implant from Intarcia
WEBSep 5, 2023 · i2o Therapeutics says it acquired the diabetes-treating assets of one-time medtech unicorn Intarcia Therapeutics. The Boston-based company acquired and integrated Intarcia’s proprietary assets and made a big personnel move. With CEO Ravi Srinivasan moving onto other opportunities, i2o named Kurt Graves as chair, president …
Insulet fully launches Omnipod 5 with Dexcom G7 in the U.S.
WEBJun 20, 2024 · Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM. It proactively corrects for highs and protects against lows with insulin dosing. The waterproof device features mobile app control for ease of use. Acton, Massachusetts-based Insulet began a limited rollout of Omnipod 5 with G7 earlier …
The 9 largest diabetes technology companies in the world
WEBAug 21, 2024 · 1. Abbott Diabetes Care — 2023 revenue: $5.761B. Abbott, one of the world’s largest medtech companies in a broader sense, takes the top spot in diabetes, too. The company’s Diabetes Care unit brought in more than $2 billion more than any other company on this list. With its Diabetes Care unit located in Alameda, California, Abbott ...
FDA grants IDE for MedAlliance’s sirolimus-eluting balloon
WEBMay 26, 2022 · MedAlliance announced today that it received FDA investigational device exemption (IDE) for its Selution SLR drug-eluting balloon. Geneva, Switzerland-based MedAlliance designed its Selution SLR (sustained limus release) novel sirolimus-eluting balloon to provide a controlled sustained drug release, similar to a drug-eluting stent.
FDA clears Abbott’s next-gen FreeStyle Libre 3 14-day CGM
WEBMay 31, 2022 · The sensor for the next-generation FreeStyle Libre 3 CGM is the same size as two U.S. pennies stacked together. [Image courtesy of Abbott] Abbott (NYSE:ABT) announced today that it received FDA clearance for its next-generation FreeStyle Libre 3 continuous glucose monitor. FDA clearance for the latest iteration of the company’s …
Lilly plans rollout of Tempo diabetes management platform
WEBNov 9, 2022 · Lilly plans a phased rollout for the platform to select clinics starting later this year, followed by national availability targeted for 2023. In the EU, the Tempo Smart Button won a CE mark on August 10. Lilly plans to begin small-scale pilots in selected European countries through partnerships with existing diabetes management ecosystems.
Novo Nordisk completes acquisition of Dicerna Pharmaceuticals
WEBDec 28, 2021 · Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed.. Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo …
Clinical Trials Archives - Page 2 of 99 - Drug Delivery Business
WEBJul 2, 2024 · Insulet (Nasdaq:PODD) today announced positive results from a type 2 diabetes pivotal trial of its Omnipod 5 automated insulin delivery system. The company recently submitted its study results to the FDA for an expansion of Omnipod 5’s indications for use. It hopes to garner clearance for the type 2 diabetes population and launch in the ...